Hematopoietic cell transplantation for pediatric myelodysplastic syndromes

2025/11/24 by Neysimélia Costa Villela, Anita Frisanco Oliveira, Roseane Vasconcelos Gouveia +3 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Acute Myeloid Leukemia Research #Blood disorders and treatments #Hematopoietic Stem Cell Transplantation

paper · pdf · doi:10.46765/2675-374x.2025v6n1e289

openalex publication_date 2025/11/24 · openalex created_date 2025/11/25 · openalex updated_date 2026/06/11

Abstract

Myelodysplastic syndromes (MDS) are uncommon in children and present distinct features compared to adults. Allogeneic hematopoietic cell transplantation (HCT) is considered the standard curative treatment for many children with MDS, including all patients with MDS with excess of blasts and those with refractory cytopenia of childhood associated with unfavorable karyotype, severe neutropenia or transfusion dependence. In this article, we reviewed the indications of HCT in pediatric MDS.

Citations

• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Discussions

• Allogeneic hematopoietic stem cell transplantation🩸 is the only curative therapy for many children with Myelodysplastic Syndrome, especially MDS with excess blasts, achieving a 5-year overall surviva [bsky, 0 points, 0 comments]

Related

• HEMATOPOIETIC CELL TRANSPLANTATION FOR JUVENILE MYELOMONOCYTIC LEUKEMIA AND OTHER MYELOPROLIFERATIVE NEOPLASMS
• Hematopoietic cell transplantationin pediatric chronic myeloid leukemia
• Hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia
• Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia
• Consensus in stem cell transplantation for pediatric solid tumors